

## Cannabinoid Hyperemesis Syndrome

**Cannabinoid hyperemesis syndrome (CHS) is a gastrointestinal condition associated with frequent and long-term use of cannabis (marijuana).**

CHS causes acute onset of recurrent episodes of severe nausea, bouts of vomiting, and intense abdominal pain that last less than 1 week. The symptoms typically start abruptly within 24 hours of the last cannabis use. People with CHS often report temporary relief of symptoms when taking hot showers or baths, which may lead to compulsive bathing.<sup>1,2</sup>

### How Common Is CHS and What Are the Risk Factors?

Although the exact number of people with CHS is unknown, based on emergency department surveys, CHS is estimated to affect about 2.75 million people in the US yearly. From 2017 to 2021, emergency department visits for CHS doubled in the US and Canada and were most common among males aged 16 to 34 years. The rise in CHS coincides with legalization of recreational cannabis and increases in delta-9-tetrahydrocannabinol (THC) concentration in cannabis products.

Risk factors for CHS include heavy cannabis use (typically daily or multiple times per day) for more than 1 year. Higher rates of CHS are reported in people who use cannabis before age 16 years, have other substance use disorders, and/or smoke cigarettes.

### How Is CHS Diagnosed?

The diagnosis of CHS can be made in people who have had 3 or more yearly episodes of nausea, vomiting, and abdominal pain that last less than 1 week, who have used cannabis more than 4 days per week for more than 1 year, and whose symptoms disappear with cannabis cessation for at least 6 months.

### What Are the Complications of CHS?

Frequent vomiting due to CHS can cause erosion of teeth enamel and may result in tooth loss. CHS may also cause dehydration, acute kidney injury, and low blood levels of chloride, potassium, sodium, and bicarbonate, which may require emergency department visits and hospitalizations. Rare severe complications of CHS include heart rhythm abnormalities, kidney failure, seizures, and death.

### Treatment for CHS

Patients who go to the emergency department with dehydration caused by CHS typically receive intravenous fluids and anti-nausea medications. Topical capsaicin (0.1%) cream applied to the upper

**Cannabinoid hyperemesis syndrome (CHS)** is a gastrointestinal condition associated with frequent and long-term use of cannabis (marijuana).

Symptoms of CHS typically start abruptly within 24 hours of last cannabis use.

- Recurring episodes of nausea and severe vomiting
- Intense abdominal pain

Potential complications of CHS include

- Erosion of teeth enamel and tooth loss due to frequent vomiting
- Dehydration, kidney damage, and low blood levels of chloride, potassium, sodium, and bicarbonate that may require hospitalization
- Rarely, heart rhythm abnormalities, seizures, kidney failure, and death

### Treatment of CHS

► Symptoms may be managed with intravenous fluids and anti-nausea drugs. Some patients may benefit from short-term use of anti-anxiety or antipsychotic drugs.

► Stopping cannabis use completely is the most effective long-term treatment but can result in withdrawal symptoms and high rates of relapse if stopped suddenly.

► Long-term management may include counseling and a tricyclic antidepressant drug.

abdomen may decrease nausea. Some patients may also benefit from acute and short-term use of benzodiazepines (anti-anxiety medication) and haloperidol (antipsychotic medication).

Complete cessation of cannabis use is the most effective long-term treatment for CHS. However, advising patients with CHS to stop cannabis use immediately may cause cannabis withdrawal symptoms and high rates of relapse. Counseling to achieve cannabis cessation and tricyclic antidepressants (such as amitriptyline) are recommended for long-term management of CHS. People with CHS who do not improve with these treatments may benefit from seeing a psychologist or psychiatrist.

### FOR MORE INFORMATION

[American College of Gastroenterology](#)

**Author:** Maria Isabel Angulo, MD

**Published Online:** October 10, 2024.  
doi:10.1001/jama.2024.9716

**Author Affiliation:** Clinical Internal Medicine–Pediatrics, University of Illinois Hospital & Health Sciences System, Chicago, Illinois.

**Conflict of Interest Disclosures:** None reported.

1. Rubio-Tapia A, McCallum R, Camilleri M. AGA clinical practice update on diagnosis and

management of cannabinoid hyperemesis syndrome. *Gastroenterology*. 2024;166(5):930-934. doi:10.1053/j.gastro.2024.01.040

2. Habboushe J, Rubin A, Liu H, Hoffman RS. The prevalence of cannabinoid hyperemesis syndrome among regular marijuana smokers in an urban public hospital. *Basic Clin Pharmacol Toxicol*. 2018; 122(6):660-662. doi:10.1111/bcpt.12962

The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be downloaded or photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, email [reprints@jamanetwork.com](mailto:reprints@jamanetwork.com).